Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.
Abstract
Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.
참고문헌 (18)
- Bergsagel D., "The incidence and epidemiology of plasma cell neoplasms", Stem Cells, 13(Suppl 2), pp.1~9 (1995)
- Corso A, "Multiple myeloma in younger patients: the role of age as prognostic factor", Ann Hematol, 76, pp.67~72 (1998)
- Blade J, "Multiple myeloma in young patients:clinical presentation and treatment approach", Leuk Lymphoma, 30, pp.493~501 (1998)
- Ludwig H, "Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group", Blood, 111, pp.4039~4047 (2008)
- Dimopoulos MA, "Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis", Leuk Lymphoma, 47, pp.1553~1556 (2006)
- Solves P, "Liver disease as primary manifestation of multiple myeloma in a young man", Leuk Res, 23, pp.403~405 (1999)
- Hogan MC, "Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult", Am J Hematol, 70, pp.55~59 (2002)
- Cheema PK, "Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant", Biol Blood Marrow Transplant, 15, pp.686~693 (2009)
- Kyle RA., "Prognostic factors in multiple myeloma", Stem Cells, 13(Suppl 2), pp.56~63 (1995)
- Bergsagel PL, "Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma", Blood, 121, pp.884~892 (2013)
- Chretien ML, "Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients", Haematologica, 99, pp.1236~1238 (2014)
- Kim K, "Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study", Am J Hematol, 89, pp.751~756 (2014)
- Koh Y, "Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide", Ann Hematol, 89, pp.201~206 (2010)
- Ailawadhi S, "Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups", Br J Haematol, 158, pp.91~98 (2012)
- Rajkumar SV, "Approach to the treatment of multiple myeloma: a clash of philosophies", Blood, 118, pp.3205~3211 (2011)
- Boyd KD, "A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial", Leukemia, 26, pp.349~355 (2012)
- Blade J, "Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years", Br J Haematol, 93, pp.345~351 (1996)
- Child JA, "High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma", N Engl J Med, 348, pp.1875~1883 (2003)